1974

History of Golf (1) The Nine Toughest Holes in the World (2) Stockie Madness (3) Bartender, One More Round for Pythium (3) Panel: 1973 Turf Problems in Review - 1974 Possible Remedies (A1-A12) Movement of Water to a Holding Pond (A13) Maintenance of Low Budget, Short Season Golf Courses (A16) Turfgrass Fertilization (A18) Determining Turfgrass Fertilizer Needs (A25) Shortage of Plant Food and How to Adjust to Supply and Cost (A29) Panel: Tricalcium Arsenate - Use and Abuse (A33-A46) Operating and Maintaining Municipal Golf Courses (A48) Maintenance of a High Budget Golf Course (A51) Trends in Agricultural Education and Where Are the Emphases (A58) Maintenance of Municipal Parks and Recreation Areas (A60) Maintenance of Grass Tennis Courts (A63) Transition from Natural to Artificial Turf (A67) Plant materials for Outlying Areas (A71) Care of University Grounds (A76) Maintenance of Industrial Sites (A79) Turfgrass Diseases and Systemic Fungicides (A81) A Look at the Future (A 84) Watering of Golf Course Turf (A92

Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2:a Phase I, open-label, dose-escalating, randomized controlled study

Objectives AGILE is a Phase Ib/IIa platform for rapidly evaluating COVID-19 treatments. In this trial (NCT04746183) we evaluated the safety and optimal dose of molnupiravir in participants with early symptomatic infection. Methods We undertook a dose-escalating, open-label, randomized-controlled (standard-of-care) Bayesian adaptive Phase I trial at the Royal Liverpool and Broadgreen Clinical Research Facility. Participants (adult outpatients with PCR-confirmed SARS-CoV-2 infection within 5 days of symptom onset) were randomized 2:1 in groups of 6 participants to 300, 600 and 800 mg doses of molnupiravir orally, twice daily for 5 days or control. A dose was judged unsafe if the probability of 30% or greater dose-limiting toxicity (the primary outcome) over controls was 25% or greater. Secondary outcomes included safety, clinical progression, pharmacokinetics and virological responses. Results Of 103 participants screened, 18 participants were enrolled between 17 July and 30 October 2020. Molnupiravir was well tolerated at 300, 600 and 800 mg doses with no serious or severe adverse events. Overall, 4 of 4 (100%), 4 of 4 (100%) and 1 of 4 (25%) of the participants receiving 300, 600 and 800 mg molnupiravir, respectively, and 5 of 6 (83%) controls, had at least one adverse event, all of which were mild (≤grade 2). The probability of ≥30% excess toxicity over controls at 800 mg was estimated at 0.9%. Conclusions Molnupiravir was safe and well tolerated; a dose of 800 mg twice daily for 5 days was recommended for Phase II evaluation